Retrospective study assessing comparison of CPX-351 and CLAG-based chemotherapy in patients with Secondary Acute Myeloid Leukemia (sAML) and AML with myelodysplastic related changes (AML-MRC)

At a glance
Trial Overview
Trial Details
- Other Details
- Related Drugs
Interventions
Results
- Publications
Authors
Trial History
References

Trial Profile

Retrospective study assessing comparison of CPX-351 and CLAG-based chemotherapy in patients with Secondary Acute Myeloid Leukemia (sAML) and AML with myelodysplastic related changes (AML-MRC)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Cytarabine/daunorubicin (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use

Most Recent Events

25 Jan 2022 New trial record
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com